The potential role of prebiotic fibre for treatment and management of non‐alcoholic fatty liver disease and associated obesity and insulin resistance
- 30 December 2011
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 32 (5), 701-711
- https://doi.org/10.1111/j.1478-3231.2011.02730.x
Abstract
Non-alcoholic fatty liver disease (NAFLD) and the more severe non-alcoholic steatohepatitis (NASH) represent a spectrum of diseases involving hepatic fat accumulation and histological features essentially identical to alcoholic liver disease; however, they occur in the absence of excessive alcohol intake. They typically arise in conjunction with one or more features of the metabolic syndrome. Lifestyle mediated weight loss remains the primary mode of therapy for NAFLD and NASH, but this is often ineffective and adjunctive medical and surgical treatments are presently lacking. Prebiotic fibres are a group of non-digestible carbohydrates that modulate the human microbiota in a manner that is advantageous to host health. Rodent studies suggest that dietary supplementation with prebiotic fibres positively impacts NAFLD by modifying the gut microbiota, reducing body fat, and improving glucoregulation. Future research should focus on placebo-controlled, human, clinical trials using histological endpoints to address the effects of prebiotics on NAFLD and NASH. The aim of this review is to summarize current knowledge about prebiotics as an emerging therapeutic target for NAFLD.This publication has 95 references indexed in Scilit:
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Recent advances in nonalcoholic fatty liver diseaseCurrent Opinion in Gastroenterology, 2010
- Mechanisms and clinical implications of hepatocyte lipoapoptosisClinical Lipidology, 2010
- Tumor necrosis factor-α accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver diseaseBiochemical and Biophysical Research Communications, 2010
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver diseaseJournal of Hepatology, 2009
- Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered miceJCI Insight, 2008
- Mechanisms underlying the resistance to diet-induced obesity in germ-free miceProceedings of the National Academy of Sciences of the United States of America, 2007
- An obesity-associated gut microbiome with increased capacity for energy harvestNature, 2006
- Obesity alters gut microbial ecologyProceedings of the National Academy of Sciences of the United States of America, 2005